IL36A and psoriasis: also employed lipid NPs to co-encapsulate erlotinib and IL36α siRNA, and revealed that this delivery system significantly reduce the secretion of inflammatory factors (IL36α, IL23, IL17, and TNF-α) in psoriatic plaques, thereby alleviating the symptoms of psoriasis (80).